Aug 05, 2025 • GlobeNewswire
NEUTRAL
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
ZUG, Switzerland, August 5, 2025 - MoonLake Immunotherapeutics ( NASDAQ:MLTX ) ( "MoonLake" or the "Company" ) , a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2025.
Jun 13, 2025 • Benzinga
SOMEWHAT-BULLISH
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co ( NYSE:MRK )
Keytruda reduced the risk of recurrence, progression, or death by 30% vs. standard of care in HNSCC patients. Median event-free survival was 59.7 months with Keytruda vs. 29.6 months with standard care. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now
Jun 06, 2025 • Benzinga
NEUTRAL
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Baker Hughes ( NASDAQ:BKR ) , Blueprint Medicines ( NASDAQ:BPMC )
PatientPoint, Infucare and Moonlake Immunotherapeutics are up for sale. Alex Jones may see his personal assets - including guns, cars, and homes - sold by the end of the year. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
Jun 04, 2025 • Zacks Commentary
NEUTRAL
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
Jun 03, 2025 • Benzinga
BULLISH
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday - Credo Technology Group ( NASDAQ:CRDO ) , Algonquin Power ( NYSE:AQN )
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of Signet Jewelers Limited SIG rose sharply during Tuesday's session after the company reported better-than-expected first-quarter financial results and raised its FY26 guidance.
Jun 03, 2025 • Benzinga
SOMEWHAT-BULLISH
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - MoonLake ( NASDAQ:MLTX ) , Merck & Co ( NYSE:MRK )
Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent expiration, Gardasil sales fall in China, and Winrevair growth underperforms.